ELSEVIER

Author Index for Volume 16

Amoroso WP, 104S
Anderson JJ, 342
Applegate WB, 41
Arango IG, 422
Armitage P, 259

Bagniewska A, 66S
Bailey LR, 30S
Baldwin W, 300
Barnes TY, 164
Barton F, 432
Bayer DP, 187
Benson V, 3
Blumenstein B, 150, 453
Blumenstein BA, 4S
Boissel J-P, 286, 319
Borok GM, 3
Brawley OW, 150, 293
Bring J, 131
Buist AS, 184, 296

CATCH Study Group, 96
Charache S, 432
Chauvin F, 319
Chernoff MC, 342
Childress JF, 408
Choi SC, 164
Clarke E, 30S
Clarke WR, 301
Cohen MC, 89
Coltman CA, Jr, 150
Comstock GW, 133
Copeland J, 331
Crowley J, 150
Curtis RC, 41

Dahlberg S, 119
Davis CE, 41
DeMets DL, 408
Dover G, 432
Doyle SR, 451
Dudl RJ, 3
Durieu I, 319

Eckert S, 432
Ellenberg SS, 408
Epstein A, 3
Epstein RS, 3

Fairweather WR, 456
Fayers P, 173
Feigl P, 150
Feldman HA, 96
Felson DT, 342
Fleming TR, 408
Ford LG, 150
Foulkes M, 408
Foulkes MA, 277, 310
Frank E, 17
Fraser WD, 299
Freedman LS, 277, 310
Friedman L, 277, 310

Gail MH, 230
Gassman JJ, 104S
Geller NL, 277, 310
George VA, 422
Gerace TA, 422
Germanson TP, 164
Gibson D, 173, 455
Girard P, 319
Goldman S, 331
Gordon DJ, 41, 277, 310
Gore SM, 289
Green SB, 189
Greenhouse J, 17
Greenhouse SW, 191, 214
Greenlick MR, 296
Griffiths RI, 377
Gueyffier F, 286

Harrington M, 270
Harvey AJ, 455
Haugh M, 286, 319
Hawkins BS, 66S, 458
Henderson WG, 331
Hertert S, 184
Heyse JF, 3
Horbar JD, 51
Hosking JD, 66S

Jadad AR, 62
James KE, 4S
Jones MF, 301

Kadane JB, 313
Kamlet MS, 17
Kelder SH, 96
Knatterud GL, 139
Koch HJ, 182
Kramer BS, 150
Kuntz TE, 104S
Kupfer D, 17

Lakatos E, 96
Leahy KA, 51
Lewis SM, 89
Lind BK, 4S
Liu P-Y, 119
LoPresti F, 30S

Mantel N, 197, 214
Martin JP, 104S
Mayer KH, 408
McBride R, 1S, 137S
McCormick M, 41
McFadden ET, 30S
McKenna C, 89
McKinlay SM, 96
McMahon RP, 432
Meinert C, 139
Meinert CL, 304, 363
Menzin J, 3
Mitchell HE, 4S
Moher D, 62
Moore R, 432
Moritz T, 331
Moses LE, 216
Mossman J, 173
Mowery R, 277, 310
Muller JE, 89
Multicenter Study of Hydroxyurea, 432
Murray DM, 96

Nader PR, 96
Newhouse MM, 66S
Ng T-H, 356
Nichol G, 62
Nony P, 319

O'Fallon J, 408
Omoigui NA, 143
Osborne ML, 184
Oster G, 3

Controlled Clinical Trials 16:460–461 (1995)
© Elsevier Science Inc. 1995
655 Avenue of the Americas, New York, NY 10010

0197-2456/95/$9.50
SSDI 0197-2456(95)00191-3

Overall JE, 451
Owen WW, 104S

Parmar MKB, 455
Paul N, 17
Penman M, 62
Piantadosi S, 202, 214, 307
Pollard RB, 408
Powe NR, 377
Prentice RL, 249

Quinn V, 3

Rahal JJ, 408
Rochon J, 449

Sande M, 408
Sato T, 359
Schneiderman MA, 193, 214
Sethi G, 331
Shih JH, 395
Simon R, 277, 310
Singer SW, 1S, 137S, 363
Stevens MT, 447
Straus S, 408

Terrin ML, 432
The SvO_2 Collaborative Group, 74
Thompson I, 150
Topol EJ, 143
Torner JC, 301
Tugwell P, 62

Uryniak TJ, 447

Vermont-Oxford Trials Network, 51
Vollmer WM, 184

Waclawiw M, 432
Wade M, 17
Walsh S, 62
Walters L, 408
Wang M, 342
Webber LS, 96
Whitley RJ, 408
Whitley-Williams P, 408
Wilkins PC, 30S
Wittes JT, 1
Wolf M, 150
Woolson RF, 301

Zucker DM, 96

ELSEVIER

Subject Index for Volume 16

ABSTRACTS
Abstracts from the Sixteenth Annual Meeting of the Society for Clinical Trials, 3S

ADHERENCE
An Empirical Evaluation of the Placebo Run-in, 41

AIDS
The Data and Safety Monitoring Board and Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials, 408
In Memoriam: David Byar as an AIDS Activist, 170

ANGIOPLASTY
Observational versus Randomized Medical Device Testing Before and After Approval—The Atherectomy-versus-Angioplasty Controversy, 143

ASSESSMENT
Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists, 62

ATHERECTOMY
Observational versus Randomized Medical Device Testing Before and After approval—The Atherectomy-versus-Angioplasty Controversy, 143

BIASED ASCERTAINMENT
Design of the Prostate Cancer Prevention Trial (TCPT), 150

BOOK REVIEWS
Clinical Data Management, ed. Rondel RK, Varley SA, and Webb, CF, 458
Drug Safety Assessment in Clinical Trials, by Sogliero-Gilbert G, 456

BYAR, DAVID P., M.D.
Byar, David P., M.D., 187

CANCER CLINICAL TRIALS
UKCCCR Register of U.K. Cancer Trials, 172

CANCER EPIDEMIOLOGY
David Byar's Approach to the Analysis of Survival Data with Covariates, 259

CHECKLISTS
Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists, 62

CHEMOPREVENTION
Design of the Prostate Cancer Prevention Trial (TCPT), 150

CLINICAL ECONOMICS
The Clinical-Economic Trial: Promise, Problems, and Challenges, 377

CLINICAL TRIALS
A Simple Measure in Defining Optimal Strata in Clinical Trials, 164

CLINICAL TRIAL
An Assessment of Data Quality in the Vermont-Oxford Trials Network Database, 51

CLINICAL TRIALS
An Empirical Evaluation of the Placebo Run-in, 41
The Clinical-Economic Trial: Promise, Problems, and Challenges, 377
Commentary regarding "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of the NIH Clinical Trialists," 307
Comments on NIH Clinical Trials Valid Analysis Requirements, 304
The Data and Safety Monitoring Board and Acquired Immune Deficiency

Controlled Clinical Trials 16:462–468 (1995)
© Elsevier Science Inc. 1995
655 Avenue of the Americas, New York, NY 10010

0197-2456/95/$9.50
SSDI 0197-2456(95)00192-1

Syndrome (AIDS) Clinical Trials, 408
David Byar's Approach to the Analysis of Survival Data with Covariates, 259
Discussion of "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists," 301
Format-Independent Data Collection Forms, 363
Inpact of the NIH Inclusion Guidelines, 300
Inclusion of Women and Minorities in Clinical Trials, 290
Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1933—The Perspective of NIH Clinical Trialists, 277
Problems and Suggested Solutions in Creating an Archive of Clinical Trials Data to Permit Later Meta-Analysis: An Example of Methotrexate Trials in Rheumatoid Arthritis, 342
Response Rates to Six Recruitment Mailing Formats and Two Messages about a Nutrition Program for Women 50–79 Years Old, 422
Response to Discussants' Letters, 310
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—the Perspective of NIH Clinical Trialists, 286, 289, 293, 296, 299
Use of Cumulative Meta-Analysis in the Design, Monitoring, and Final Analysis of a Clinical Trial: A Case Study, 331

CLINIMETRICS
Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists, 62

CLUSTER RANDOMIZATION
Statistical Design of the Child and Adolescent Trial for Cardiovascular Health (CATCH): Implications of Cluster Randomization, 96

COMMUNITY STUDIES
Statistical Design of the Child and Adolescent Trial for Cardiovascular Health (CATCH): Implications of Cluster Randomization, 96

COORDINATING CENTERS
Functions and Organization of Coordinating Centers for Multicenter Studies, 4S

COST-BENEFIT STUDIES
The Clinical-Economic Trial: Promise, Problems, and Challenges, 377

COST EFFECTIVENESS
A Randomized Trial to Assess Effectiveness and Cost in Clinical Practice: Rationale and Design of the Cholesterol Reduction Intervention Study (CRIS), 3

COST-EFFECTIVENESS STUDIES
The Clinical-Economic Trial: Promise, Problems, and Challenges, 377

COST-UTILITY ANALYSIS
Cost Utility Analysis of Maintenance Treatment for Recurrent Depression, 17

CRITICALLY ILL PATIENT
The SvO_2 Study, General Design and Results of the Feasibility Phase of a Multicenter, Randomized Trial of Three Different Hemodynamic Approaches and Two Monitoring Techniques in the Treatment of Critically Ill Patients, 74

DATA AND SAFETY MONITORING BOARDS
The Data and Safety Monitoring Board and Acquired Immune Deficiency Syndrome (AIDS) Clinical Trials, 408

DATA COLLECTION
Format-Independent Data Collection Forms, 363

DATA ENTRY
Response to Dr. Blumenstein's Letter (letter), 455

DATA MANAGEMENT
Approaches to Data Management, 30S
Data Collection and Transcription, 66S
Data Management for Multicenter Studies: Methods and Guidelines, 1S
Data Quality Assurance, Monitoring, and Reporting, 104S
Interim Reports, Participant Closeout, and Study Archives, 137S

DATA QUALITY
An Assessment of Data Quality in the Vermont-Oxford Trials Network Database, 51

DATABASE
An Assessment of Data Quality in the Vermont-Oxford Trials Network Database, 51

DAVID BYAR
David Byar's Approach to the Analysis of Survival Data with Covariates, 259

DEVICE APPROVAL
Observational versus Randomized Medical Device Testing Before and After Approval—The Atherectomy-versus-Angioplasty Controversy, 143

DISCRIMINANT REGIONS
A Simple Measure in Defining Optimal Strata in Clinical Trials, 164

DISEASE PREVENTION TRIALS
On the Role, Design, and Analysis of Disease Prevention Trials, 249

DOSE RANGING
Dose-Ranging Trials: Guidelines for Data Collection and Standardized Descriptions, 319

DRUG THERAPY
A Randomized Trial to Assess Effectiveness and Cost in Clinical Practice: Rationale and Design of the Cholesterol Reduction Intervention Study (CRIS), 3

ECONOMIC INVESTIGATION
The Clinical-Economic Trial: Promise, Problems, and Challenges, 377

EDUCATION
An Empirical Evaluation of the Placebo Run-in, 41

ELICITATION
Prime Time for Bayes, 313

EPIDEMIOLOGIC METHODS
The Clinical-Economic Trial: Promise, Problems, and Challenges, 377

EPIDEMIOLOGY
David Byar's Contribution to Epidemiology, 230

EQUIVALENCE STUDIES
Conventional Null Hypothesis Testing in Active Control Equivalence Studies, 356

ERROR RATES
An Assessment of Data Quality in the Vermont-Oxford Trials Network Database, 51

FETAL HEMOGLOBIN
Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia, 432

FIRST ADMINISTRATION
Dose-Ranging Trials: Guidelines for Data Collection and Standardized Descriptions, 319

FISHER's LSD APPROACH
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119

FOLLOW-UP STUDIES
Format-Independent Data Collection Forms, 363

FOOD AND DRUG ADMINISTRATION
Observational versus Randomized Medical Device Testing Before and After Approval—The Atherectomy-versus-Angioplasty Controversy, 143

FORM PRODUCTION
Format-Independent Data Collection Forms, 363

GROUP RANDOMIZATION
Statistical Design of the Child and Adolescent Trial for Cardiovascular Health (CATCH): Implications of Cluster Randomization, 96

HEAD INJURY
A Simple Measure in Defining Optimal Strata in Clinical Trials, 164

HEMODYNAMICS
The SvO_2 Study: General Design and Results of the Feasibility Phase of a Multicenter, Randomized Trial of Three Different Hemodynamic Approaches and Two Monitoring Techniques in the Treatment of Critically Ill Patients, 74

HOTELLINGS T^2
Comment on the Substitution of z for t and on Hotelling's T^2 for Repeated Measures (letter), 451

HYDROXYUREA
Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia, 432

HYPERCHOLESTEROLEMIA
A Randomized Trial to Assess Effectiveness and Cost in Clinical Practice: Rationale and Design of the Cholesterol Reduction Intervention Study (CRIS), 3

INTENSIVE CARE
The SvO_2 Study: General Design and Results of the Feasibility Phase of a Multicenter, Randomized Trial of Three Different Hemodynamic Approaches and Two Monitoring Techniques in the Treatment of Critically Ill Patients, 74

INTENTION-TO-TREAT PRINCIPLE
Statistical Design of the Child and Adolescent Trial for Cardiovascular Health (CATCH): Implications of Cluster Randomization, 96

INTERACTIONS
David Byar's Approach to the Analysis of Survival Data with Covariates, 259

INTERIM REPORTING
Interim Reports, Participant Closeout, and Study Archives, 137S

LAG TIME
Sample Size Calculation for Complex Clinical Trials with Survival Endpoints, 395

LEAST FAVORABLE ALTERNATIVE
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119

LETTERS TO THE EDITOR
Comment on the Substitution of z for t and on Hotelling's T^2 for Repeated Measures, 451
A Further Look at the Cochran-Mantel-Haenszel Risk Difference, 359
Medical Research Data, 453
Response to Dr. Blumenstein's Letter, 455
Response to S.J. Day's Letter, 447
Sample Size Calculations for Repeated Measures Experiments, 449

LOGRANK TEST
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119

LOSS FUNCTION
Prime Time for Bayes, 313

MAILINGS
Response Rates to Six Recruitment Mailing Formats and Two Messages about a Nutrition Program for Women 50–79 Years Old, 422

MANTEL–HAENSZEL STATISTIC
A Simple Measure in Defining Optimal Strata in Clinical Trials, 164

MARK-UP LANGUAGE
Format-Independent Data Collection Forms, 363

MARKOV MODEL
Sample Size Calculation for Complex Clinical Trials with Survival Endpoints, 395

MEASUREMENT
Comment on the Substitution of z for t and on Hotelling's T^2 for Repeated Measures (letter), 451

META-ANALYSIS
Problems and Suggested Solutions in Creating an Archive of Clinical Trials Data to Permit Later Meta-Analysis: An Example of Methotrexate Trials in Rheumatoid Arthritis, 342
Use of Cumulative Meta-Analysis in the Design, Monitoring, and Final Analysis of a Clinical Trial: A Case Study, 331

MINORITIES
Commentary Regarding "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993–The Perspective of NIH Clinical Trialists," 307
Comments on NIH Clinical Trials Valid Analysis Requirements, 304
Discussion of "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993–The

Perspective of NIH Clinical Trialists," 301
Inclusion of Women and Minorities in Clinical Trials, 290
Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1933—The Perspective of NIH Clinical Trialists," 277
Response to Discussants' Letters, 310
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists," 286, 289, 293, 296, 299

MIXTURE SURVIVAL MODEL
Cost Utility Analysis of Maintenance Treatment for Recurrent Depression, 17

MONITORING TECHNIQUES
Design of the Prostate Cancer Prevention Trial (TCPT), 150

MONTE CARLO SIMULATION
Cost Utility Analysis of Maintenance Treatment for Recurrent Depression, 17

MULTICENTER STUDIES
Data Management for Multicenter Studies: Methods and Guidelines, 1S
Functins and Organization of Coordinating Centers for Multicenter Studies, 4S

MULTILEVEL MODELING
Statistical Design of the Child and Adolescent Trial for Cardiovascular Health (CATCH): Implications of Cluster Randomization, 96

MULTIPLE COMPARISON
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119

NEONATE
An Assessment of Data Quality in the Vermont-Oxford Trials Network Database, 51

NETWORK
An Assessment of Data Quality in the Vermont-Oxford Trials Network Database, 51

NIH REVITALIZATION ACT
Commentary Regarding "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists," 307
Comments on NIH Clinical Trials Valid Analysis Requirements, 304
Discussion of "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists," 301
Impact of the NIH Inclusion Guidelines, 300
Inclusion of Women and Minorities in Clinical Trials, 290
Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1933—The Perspective of NIH Clinical Trialists, 277
Response to Discussants' Letters, 310
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—the Perspective of NIH Clinical Trialists," 286, 289, 293, 296, 299

NONPROPORTIONAL HAZARDS
Sample Size Calculation for Complex Clinical Trials with Survival Endpoints, 395

NULL HYPOTHESIS
Conventional Null Hypothesis Testing in Active Control Equivalence Studies, 356

OBJECTIVITY
Prime Time for Bayes, 313

OBSERVATIONAL DATA
Observational versus Randomized Medical Device Testing Before and After Approval–The Atherectomy-versus-Angioplasty Controversy, 143

OPTICAL CATHETER
The SvO_2 Study: General Design and Results of the Feasibility Phase of a Multicenter, Randomized Trial of Three Different Hemodynamic Approaches and Two Monitoring Techniques in the Treatment of Critically Ill Patients, 74

OXYGEN DELIVERY
The SvO_2 Study: General Design and Results of the Feasibility Phase of a

Multicenter, Randomized Trial of Three Different Hemodynamic Approaches and Two Monitoring Techniques in the Treatment of Critically Ill Patients, 74

PARTICIPANT CLOSEOUT
Interim Reports, Participant Closeout, and Study Archives, 137S

PHASE I STUDY
Dose-Ranging Trials: Guidelines for Data Collection and Standardized Descriptions, 319

PLACEBO
An Empirical Evaluation of the Placebo Run-in, 41

POSTERIOR DISTRIBUTION
Prime Time for Bayes, 313

POWER
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119

PREOPERATIVE RISK ASSESSMENT
Requirements for Controlled Clinical Trials of Preoperative Cardiovascular Risk Reduction, 89

PREOPERATIVE CARDIAC TESTING
Requirements for Controlled Clinical Trials of Preoperative Cardiovascular Risk Reduction, 89

PREVENTION TRIALS
Response Rates to Six Recruitment Mailing Formats and Two Messages about a Nutrition Program for Women 50–79 Years old, 422

PRIOR DISTRIBUTION
Prime Time for Bayes, 313

PROSTATE CANCER
Design of the Prostate Cancer Prevention Trial (TCPT), 150

PROTOCOL
Dose-Ranging Trials: Guidelines for Data Collection and Standardization Descriptions, 319

PULMONARY FUNCTION TESTS
Response to S.J. Day Letter (letter), 447

QUALITY
Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists, 62

QUALITY ASSURANCE
Data Quality Assurance, Monitoring, and Reporting, 104S

RANDOMIZED CLINICAL TRIAL
A Randomized Trial to Assess Effectiveness and Cost in Clinical Practice: Rationale and Design of the Cholesterol Reduction Intervention Study (CRIS), 3

RANDOMIZED CONTROLLED TRIALS
The Clinical-Economic Trial: Promise, Problems, and Challenges, 377
Observational versus Randomized Medical Device Testing Before and After Approval – The Atherectomy-versus-Angioplasty Controversy, 143

RECRUITMENT
Response Rates to Six Recruitment Mailing Formats and Two Messages about a Nutrition Program for Women 50–79 Years Old, 422

RECURRENT DEPRESSION
Cost Utility Analysis of Maintenance Treatment for Recurrent Depression, 17

REGISTER OF TRIALS
UKCCCR Register of U.K. Cancer Trials, 172

REPEATED MEASURES EXPERIMENTS
Sample Size Calculations for Repeated Measures Experiments (letter), 449

RESPONSE RATES
Response Rates to Six Recruitment Mailing Formats and Two Messages about a Nutrition Program for Women 50–79 Years Old, 422

RISK DIFFERENCE ESTIMATORS
A Further Look at the Cochran-Mantel-Haenszel Risk Difference (letter), 359

RUN-IN
An Empirical Evaluation of the Placebo Run-in, 41

SAMPLE SIZE
Comment in the Substitution of z for t and on Hotelling's T^2 for Repeated Measures (letter), 451
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119
Sample Size Calculations for Repeated Measures Experiments (letter), 449

SCALES
Assessing the Quality of Randomized Controlled Trials: An Annotated Bibliography of Scales and Checklists, 62

SICKLE CELL ANEMIA
Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia, 432

SICKLE CELL CRISES PREVENTION
Design of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia, 432

SOCIETY FOR CLINICAL TRIALS
Sixteenth Annual Meeting, 3S

STANDARDS
Dose-Ranging Trials: Guidelines for Data Collection and Standardized Descriptions, 319

STRATIFICATION
A Simple Measure in Defining Optimal Strata in Clinical Trials, 164

STUDY ARCHIVING
Interim Reports, Participant Closeout, and Study Archives, 137S

SUBJECTIVITY
Prime Time for Bayes, 313

SURVIVAL ANALYSIS WITH COVARIATES
David Byar's Approach to the Analysis of Survival Data with Covariates, 259

SURVIVAL ENDPOINTS
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119

THERAPEUTIC TRIALS
On the Role, Design, and Analysis of Disease Prevention Trials, 249

TIME-DEPENDENT RATES
Sample Size Calculation for Complex Clinical Trials with Survival Endpoints, 295

TRIAL REGISTRY
UKCCCR Register of U.K. Cancer Trials, 172

TYPE I ERROR
Design and Analysis of Multiarm Clinical Trials with Survival Endpoints, 119

UNCONDITIONAL POWER
Sample Size Calculation for Complex Clinical Trials with Survival Endpoints, 295

UTILITY FUNCTION
Prime Time for Bayes, 313

VALID ANALYSIS
Comments on NIH Clinical Trials Valid Analysis Requirements, 304

WOMEN
Commentary Regarding "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists," 307
Comments on NIH Clinical Trials Valid Analysis Requirements, 304
Discussion of "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists," 301
Inclusion of Women and Minorities in Clinical Trials, 290
Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists, 277
Response to Discussants' Letters, 310
Response to "Inclusion of Women and Minorities in Clinical Trials and the NIH Revitalization Act of 1993—The Perspective of NIH Clinical Trialists," 286, 289, 293, 296, 299